scholarly journals New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus

2012 ◽  
Vol 14 (3) ◽  
pp. R103 ◽  
Author(s):  
Fang-Fang Wang ◽  
Li-An Zhu ◽  
Yu-Qiong Zou ◽  
Hui Zheng ◽  
Alisa Wilson ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Migration Inhibitory Factor ◽  
Lupus Erythematosus ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Macrophage Migration ◽  
Systemic Lupus ◽  
Steroid Resistant

scholarly journals Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus

2018 ◽  
Vol 5 (1) ◽  
pp. e000277 ◽  
Author(s):  
Fabien B Vincent ◽  
Laura Slavin ◽  
Alberta Y Hoi ◽  
Arthur Richard Kitching ◽  
Fabienne Mackay ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Renal Disease ◽  
Disease Activity ◽  
Migration Inhibitory Factor ◽  
Lupus Erythematosus ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Inactive Disease ◽  
Macrophage Migration ◽  
Systemic Lupus

ObjectiveTo characterise the clinical relevance of urinary macrophage migration inhibitory factor (uMIF) concentrations in patients with systemic lupus erythematosus (SLE).MethodsMIF, adjusted for urine creatinine, was quantified by ELISA in urine samples from 64 prospectively recruited patients with SLE. Serum MIF and urinary monocyte chemoattractant protein 1 (uMCP-1) were quantified by ELISA in a subset of patients (n = 39). Disease activity was assessed using the SLE Disease Activity Index-2000 (SLEDAI-2K) score.ResultsuMIF was detectable in all patients with SLE. uMIF was positively correlated with overall SLEDAI-2K, was significantly higher in patients with SLE with high disease activity (SLEDAI-2K≥10) compared with those with inactive disease (SLEDAI-2K<4), and this association remained significant after adjusting for ethnicity, flare and use of immunosuppressants. uMIF was also significantly higher in SLE patients with flare of disease, although not confirmed in multivariable analysis. No significant differences in uMIF levels were observed according to the presence of renal disease activity, as assessed by renal SLEDAI-2K or biopsy-confirmed lupus nephritis. In contrast, uMCP-1 was significantly higher in SLE patients with active renal disease. uMIF expression was not associated with irreversible organ damage accrual or glucocorticoid use.ConclusionsThese data suggest uMIF as a potential overall but not renal-specific SLE biomarker, whereas uMCP-1 is a renal-specific SLE biomarker.

Sign in / Sign up

Export Citation Format

Share Document